Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17481374 | 0.86 | MAPT (0.49) | MAPTALDH1A1MAPK1POLBTDP1 | |
| SCHEMBL16084465 | 0.83 | MAPT (0.44) | MAPTALDH1A1MAPK1POLBTDP1 | |
| SCHEMBL9984130 | 0.76 | MAPT (0.49) | MAPTALDH1A1MAPK1POLBTDP1 | |
| SCHEMBL15653173 | 0.75 | MAPT (0.46) | MAPTALDH1A1MAPK1POLBTDP1 | |
| SCHEMBL9983819 | 0.75 | SMN1; SMN2 (0.53) | MAPTALDH1A1MAPK1TDP1CYP1A2 | |
| SCHEMBL9985385 | 0.75 | MAPT (0.48) | MAPTALDH1A1MAPK1POLBTDP1 | |
| SCHEMBL9983596 | 0.75 | MAPT (0.51) | MAPTALDH1A1MAPK1POLBTDP1 | |
| SCHEMBL9984089 | 0.75 | MAPT (0.51) | MAPTALDH1A1MAPK1POLBTDP1 | |
| SCHEMBL2195050 | 0.75 | MAPT (0.49) | MAPTALDH1A1MAPK1POLBTDP1 | |
| SCHEMBL2194577 | 0.75 | TXNRD1 (0.38) | MAPTMAPK1TDP1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970277-B1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KNOPP BIOSCIENCES LLC (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-2970277-B1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KNOPP BIOSCIENCES LLC (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20190002464-A1 | IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2019-01-03 | — | — | US | disclosed |
| US-20190002464-A1 | IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2019-01-03 | — | — | US | disclosed |
| US-10106536-B2 | Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2018-10-23 | — | — | US | disclosed |
| US-20170240547-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2017-08-24 | — | — | US | disclosed |
| US-20170240547-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2017-08-24 | — | — | US | disclosed |
| US-20170240547-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2017-08-24 | — | — | US | disclosed |
| US-9650376-B2 | Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650376-B2 | Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650376-B2 | Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160031875-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2016-02-04 | — | — | US | disclosed |
| US-20160031875-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2016-02-04 | — | — | US | disclosed |
| US-20160031875-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2016-02-04 | — | — | US | disclosed |
| EP-2970277-A2 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | Knopp Biosciences LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014145852-A2 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KNOPP BIOSCIENCES LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014145852-A2 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KNOPP BIOSCIENCES LLC (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106536-B2 | Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators | KCNA7, KCNA2, KCNK17 | MAPT 2289/4885ALDH1A1 1535/4885MAPK1 1790/4885 |
| US-20160031875-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KCNA7, KCNA2, KCNK17 | MAPT 2289/4885ALDH1A1 1535/4885MAPK1 1790/4885 |
| US-20190002464-A1 | IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KCNA7, KCNA2, KCNK17 | MAPT 2332/4885ALDH1A1 1531/4885MAPK1 1718/4885 |
| US-20170240547-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KCNA7, KCNA2, KCNK17 | MAPT 2289/4885ALDH1A1 1535/4885MAPK1 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.